http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-9704774-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da54f7ebbd2d9d8a82f92aca4d1b4e48 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J53-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J71-0005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-34 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J71-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J53-00 |
| filingDate | 1995-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86fc6cba815b2d91fa136dc5a63d57f2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4fcc653857f5dbc70058d0022b4fb59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fde51a25dfb1f36af02a421550bce10e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69f32d2fa709c3c7939390217fb4204a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66a6fc4b24bc915e3b31b4d62629bf68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f8841504e6e5be7a9c112290f963af1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49a7c62ea49d3994425097aa082531d5 |
| publicationDate | 1997-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-9704774-A |
| titleOfInvention | DERIVATIVES OF 19-NOR-PROGESTERONE BRIDGED IN C2 14ALFA, 17ALFA. |
| abstract | The invention relates to C2 14, 17 bridged steroids of the general formula 1, wherein R3 represents one oxygen atom, the hydroxyamino group or two hydrogen atoms; R6 represents either a hydrogen, fluorine, chlorine or bromine atom or a C1-C4 alkyl group in the alpha or beta position, R6 and R7 then represent hydrogen atoms; or alternatively, R6 represents a hydrogen, fluorine, chlorine or bromine atom or a C1-C4 alkyl group, R6 and R7 then represent a further common bond; R7 represents a C1-C4 alkyl group in the alpha or beta position; R6 and R6 'then represent hydrogen atoms or alternatively R6 and R7 together represent a hydrogen atom; or R6 and R6 'together represent an ethylene or methylene group and R7 represent a hydrogen atom; R9 and R10 each represent a hydrogen atom or a common bond; R11 and R12 each represent a hydrogen atom or a common bond; R13 represents a methyl or ethyl group; R15 represents a hydrogen atom or a C1-C3 alkyl group; R16 and R16 'independently of each other represent a hydrogen atom, a C1-C3 alkyl group or a C2-C4 alkenyl group or together represent a C1-C3 alkylidene group; R15 and R16 represent a common bond and R16 'represents a hydrogen atom or a C1-C3 alkyl group or alternatively R15 and R16 together represent a ring of the partial formula (i) shown, in which N = 1 and 2 and X represents a methylene group or an oxygen atom; and R16 'represents a hydrogen atom; R17ü represents a hydrogen atom or a C1-C3 alkyl group; R17² represents a hydrogen atom, a C1-C3 alkyl group or a C2-C4 alkenyl group; R17ü and R17² each represent a hydrogen atom or a common bond; R²ü represents a hydrogen atom or a C1-C3 alkyl group and R²ü represents a hydrogen atom, a C1-C3 alkyl group or a hydroxy group. The claimed compounds do not include 14, 17-ethane-19-norpregn-4-en 3,20-dione. The new compounds, unlike the one not claimed, show a high level of gestagenic activity even after peroral administration and are suitable for use in the production of drugs. |
| priorityDate | 1994-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.